Pfizer buys two Baxter vaccines

Share this article:

Pfizer is spending $635 million to broaden its vaccines portfolio. Reuters reports that the company is purchasing two vaccines from Baxter. Both vaccines are sold outside of the United States. One vaccine is for meningitis, the other for encephalitis. The two earned around $300 million combined last year.

The purchase is part of Baxter's decision to split into Baxter BioScience, which is focused on blood disorders, and Baxter, which will sell products including IV solutions and equipment.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters